We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

1 Day TEVA 1.97% DJIA 0.02% S&P 500 0.24% Health Care/Life Sciences 0.00% ...